Literature DB >> 2024973

Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers.

J H Yuk1, C H Nightingale, R Quintiliani, K R Sweeney.   

Abstract

The pharmacokinetics and bioavailability of ofloxacin in 20 healthy male volunteers were studied in an open-label, randomized, two-way crossover study. Ofloxacin (400 mg) was administered either as a 1-h infusion or as an oral tablet. The mean peak concentration after intravenous infusion was 4.30 +/- 0.69 microgram/ml, and that after oral administration was 3.14 +/- 0.53 microgram/ml, occurring 1.74 +/- 0.57 h after dosing. The bioavailability (F) of the oral dosage form of ofloxacin was virtually identical to that of the intravenous form (F = 105% +/- 7%). This complete bioavailability of ofloxacin is supportive of the use of the oral dosage form for the treatment of infections in hospitalized patients either as a replacement for intravenous ofloxacin therapy or in streamlining therapy from the intravenous to the oral route.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2024973      PMCID: PMC245013          DOI: 10.1128/AAC.35.2.384

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.

Authors:  R Wise; D Griggs; J M Andrews
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

2.  Pharmacokinetics of ofloxacin after parenteral and oral administration.

Authors:  H Lode; G Höffken; P Olschewski; B Sievers; A Kirch; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

3.  Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects.

Authors:  R Farinotti; J H Trouvin; V Bocquet; N Vermerie; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

4.  Pharmacokinetics of ofloxacin. An overview.

Authors:  S Flor
Journal:  Am J Med       Date:  1989-12-29       Impact factor: 4.965

Review 5.  Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application.

Authors:  R H Drew; H A Gallis
Journal:  Pharmacotherapy       Date:  1988       Impact factor: 4.705

6.  Comparative pharmacokinetics of new quinolones.

Authors:  H Lode; G Höffken; C Prinzing; P Glatzel; R Wiley; P Olschewski; B Sievers; D Reimnitz; K Borner; P Koeppe
Journal:  Drugs       Date:  1987       Impact factor: 9.546

  6 in total
  15 in total

1.  Distribution and binding kinetics of ciprofloxacin and ofloxacin in the hindlimb of the rat.

Authors:  A Sanchez-Navarro; A C Casquero-Dorado; M Weiss
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

2.  Milk and yoghurt do not impair the absorption of ofloxacin.

Authors:  P J Neuvonen; K T Kivistö
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

Review 3.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

4.  Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.

Authors:  S Thee; A J Garcia-Prats; H M McIlleron; L Wiesner; S Castel; J Norman; H R Draper; P L van der Merwe; A C Hesseling; H S Schaaf
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

Review 5.  Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation.

Authors:  A Sánchez-Navarro; M M Sánchez Recio
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

6.  Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers.

Authors:  S C Flor; M C Rogge; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

7.  Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.

Authors:  M E Klepser; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

8.  Lack of effect of amoxycillin on the absorption of ofloxacin.

Authors:  G Paintaud; G Alván; U Hellgren; I Nilsson-Ehle
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.

Authors:  B JI; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

10.  Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.

Authors:  Die Cheng; Wei-Ren Xu; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.